Generic Eliquis Sprinkle Availability

Last updated on Jun 11, 2025.

See also: Generic Eliquis

Eliquis Sprinkle is a brand name of apixaban, approved by the FDA in the following formulation(s):

ELIQUIS SPRINKLE (apixaban - for suspension;oral)

• Manufacturer: BRISTOL
  Approval date: April 17, 2025
  Strength(s): 0.15MG ^[RLD]

Is there a generic version of Eliquis Sprinkle available?

No. There is currently no therapeutically equivalent version of Eliquis Sprinkle available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eliquis Sprinkle. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Apixaban formulations
  Patent 11,896,586
  Issued: February 13, 2024
  Inventor(s): Badawy; Sherif Ibrahim Farag et al.
  Assignee(s): Bristol-Myers Squibb Company (Princeton, NJ); Pfizer Inc. (New York, NY)
  

  Apixaban pharmaceutical formulation is provided. Also provided is a use of the apixaban formulation in treatment of a thromboembolic disorder.

  Patent expiration dates:

  • November 22, 2040
    
    ✓ 
    Patent use: TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT FROM 2.6 TO LESS THAN 4 KG
    ✓ 
    Drug product
• Apixaban formulations
  Patent 11896586*PE
  Issued: February 13, 2024
  Inventor(s): Badawy; Sherif Ibrahim Farag et al.
  Assignee(s): Bristol-Myers Squibb Company (Princeton, NJ); Pfizer Inc. (New York, NY)
  

  Apixaban pharmaceutical formulation is provided. Also provided is a use of the apixaban formulation in treatment of a thromboembolic disorder.

  Patent expiration dates:

  • May 22, 2041
    
• Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
  Patent 6,967,208
  Issued: November 22, 2005
  Inventor(s): Pinto; Donald J. P. et al.
  Assignee(s): Bristol-Myers Squibb Pharma Company (Princeton, NJ)
  

  The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1##
  or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  Patent expiration dates:

  • November 21, 2026
    
    ✓ 
    Patent use: TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT FROM 2.6 TO LESS THAN 4 KG
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
  Patent 6967208*PED
  Issued: November 22, 2005
  Inventor(s): Pinto; Donald J. P. et al.
  Assignee(s): Bristol-Myers Squibb Pharma Company (Princeton, NJ)
  

  The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1##
  or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  Patent expiration dates:

  • May 21, 2027
    
    ✓ 
    Pediatric exclusivity

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • April 17, 2028 - NEW PRODUCT
  • October 17, 2028 - PEDIATRIC EXCLUSIVITY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer